Pacira Biosciences Inc (NASDAQ:PCRX) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,160,000 shares, an increase of 10.9% from the January 15th total of 3,750,000 shares. Based on an average daily volume of 479,300 shares, the short-interest ratio is presently 8.7 days. Approximately 10.3% of the shares of the stock are short sold.
Shares of PCRX stock traded up $0.93 during trading hours on Friday, hitting $49.99. 600,443 shares of the company’s stock were exchanged, compared to its average volume of 474,234. The stock’s 50-day moving average is $44.64 and its 200-day moving average is $41.94. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.95 and a quick ratio of 3.32. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 1,249.75, a price-to-earnings-growth ratio of 1.17 and a beta of 1.31. Pacira Biosciences has a 52 week low of $34.64 and a 52 week high of $51.00.
Several research firms have recently weighed in on PCRX. Cowen reaffirmed a “hold” rating and issued a $41.00 target price on shares of Pacira Biosciences in a report on Thursday, November 7th. Royal Bank of Canada reiterated a “buy” rating on shares of Pacira Biosciences in a research report on Wednesday, December 18th. Wedbush reissued a “buy” rating and set a $85.00 price target on shares of Pacira Biosciences in a report on Tuesday, January 7th. BTIG Research initiated coverage on shares of Pacira Biosciences in a research report on Wednesday, November 6th. They issued a “buy” rating and a $56.00 price target on the stock. Finally, Zacks Investment Research cut shares of Pacira Biosciences from a “strong-buy” rating to a “hold” rating and set a $47.00 price objective on the stock. in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. Pacira Biosciences currently has an average rating of “Hold” and a consensus target price of $53.17.
Several large investors have recently made changes to their positions in the company. Usca Ria LLC bought a new position in shares of Pacira Biosciences in the third quarter worth about $38,000. Quantbot Technologies LP bought a new stake in shares of Pacira Biosciences during the fourth quarter valued at approximately $56,000. LS Investment Advisors LLC acquired a new stake in shares of Pacira Biosciences in the third quarter valued at approximately $50,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Pacira Biosciences in the first quarter valued at approximately $65,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Pacira Biosciences by 23.0% in the third quarter. Steward Partners Investment Advisory LLC now owns 2,029 shares of the company’s stock valued at $77,000 after purchasing an additional 379 shares in the last quarter.
About Pacira Biosciences
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Recommended Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.